Gene therapy for retinal degeneration

Project Information

FRANKC.SCHLICHTENBRE

Grant agreement ID: QLK3-CT-1999-51190

Project closed

Start date 26 June 2000

End date 25 June 2002

Funded under

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Total cost € 114 072,00

EU contribution € 114 072,00

Coordinated by

UNIVERSITY COLLEGE LONDON
United Kingdom

Objective

Retinal degenerations are a major cause of blindness in the European Union. The aim of this proposal is to develop somatic gene therapy for these conditions. The central issue which must be addressed is the safe and efficient delivery of therapeutic genes to photoreceptor cells. In this proposal we aim to improve our delivery system and assess its efficacy in an animal model.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• medical and health sciences › medical biotechnology › genetic engineering › gene therapy

You need to log in or register to use this function

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-3. - Key action The "Cell factory"

Call for proposal

Data not available

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

UNIVERSITY COLLEGE LONDON

• EU contribution: No data
• Address: Bath Street 11-43 ; EC1V 9EL LONDON ; United Kingdom
• Total cost: No data